NICE Rejects Avastin For Ovarian Cancer On Cost, Okays Lucentis
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.